Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Market-Moving News for November 4th

Author: Benzinga Newsdesk | November 04, 2025 07:24am

PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patients With Myeloproliferative Neoplasms

 

NSP: -32% | Insperity shares are trading lower after the company reported worse-than-expected Q3 financial results and cut its FY25 adjusted EPS and GAAP EPS guidance below estimates. Also, the company issued Q4 adjusted EPS and GAAP EPS guidance below estimates.

 

SRPT: -41% | Sarepta Therapeutics shares are trading lower after the company reported Q3 financial results. Also, the company announced that its ESSENCE study did not achieve statistical significance on its primary endpoint.

Posted In: NSP PRLD SRPT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist